Treating Glioblastoma Using Integrin Pathway Targeting
Summary
USPTO granted patent US12601743B2 to The Regents of the University of California for methods of treating drug-resistant glioblastoma (GBM) by targeting the integrin avb3 pathway. The patent covers diagnostic methods to determine tumor sensitivity and treatment methods for tumors identified as avb3+ and Glut3+ with specific molecular signatures. The patent contains 9 claims.
What changed
USPTO granted patent US12601743B2 to The Regents of the University of California covering methods for treating glioblastoma (GBM) by targeting the integrin avb3 pathway. The patent includes methods for determining tumor sensitivity based on expression of avb3+ and Glut3+ markers along with specific genetic signatures associated with Classical or Proneural molecular subtypes.
For pharmaceutical and biotechnology companies, this patent establishes exclusive rights for integrin pathway targeting in glioblastoma treatment. Companies developing similar cancer therapies should conduct freedom-to-operate analyses. Research institutions and drug developers may seek licensing opportunities for the protected methods.
What to do next
- Monitor for patent licensing opportunities
- Review patent claims for freedom-to-operate analysis
Archived snapshot
Apr 14, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Methods for treating drug resistant cancers
Grant US12601743B2 Kind: B2 Apr 14, 2026
Assignee
The Regents of the University of California
Inventors
David Cheresh, Sara Weis, Erika Cosset
Abstract
Provided are methods for determining whether a glioblastoma (GBM) tumor or GBM cancer cell will be sensitive to a treatment targeting the integrin avb3 (αvβ3) pathway, comprising determining whether the GBM tumor or the GBM cancer cell expresses both avb3+ and Glut3+ along with a specific genetic signature associated with Glut3 addiction, where in alternative embodiments a cell is Glut3 addiction if the GBM tumor or the GBM cancer cell has markers consistent with the Classical or the Proneural molecular subtypes of GBM, or, expresses markers consistent with a Glut3-addicted molecular signature, e.g., as listed in FIG. 11 or FIG. 23. Also provided herein are methods of treating glioblastoma (GBM) tumors found to be sensitive to agents targeting or inhibiting the integrin avb3 (αvβ3) pathway, wherein the sensitivity is determined by methods as provided herein.
CPC Classifications
C07K 16/2863 C07K 16/28 C07K 16/2848 C07K 16/30 C07K 2317/569 C07K 2317/622 C07K 14/70557 C07K 14/705 C07K 14/70546 G01N 33/68 G01N 33/574 G01N 33/57492 G01N 33/6872
Filing Date
2023-05-09
Application No.
18195184
Claims
9
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.